耳鼻咽喉科

订阅

MedSci主页 / 所有栏目 / 耳鼻咽喉科

Sci Rep：EYA4变异引起的听力损失患病率和临床特性研究

2020-03-17 AlexYang MedSci原创

听力损失 临床特征 基因变异
关注

已知EYA4基因变异能够导致常染色体显性非综合征遗传听力损失，DFNA10。到目前为止，在不同的民族中已经鉴定了30个变异与听力损失有关。为了更高的理解DFNA10的临床特征和流行情况，研究人员在一个

已知EYA4基因变异能够导致常染色体显性非综合征遗传听力损失，DFNA10。到目前为止，在不同的民族中已经鉴定了30个变异与听力损失有关。为了更高的理解DFNA10的临床特征和流行情况，研究人员在一个大的日本听力损失患者群体中对EYA4变异进行了遗传筛选。

研究选择了1336名常染色体显性听力损失患者作为研究群体，并对所有患者的68个基因进行了靶向基因组富集和大规模平行测序。EYA4变异的临床案例信息从医疗记录中收集并分析。研究人员在1336个常染色体显性听力损失家族的中12个渊源者中发现了11个新的EYA4变异（三个移码突变、三个错义突变、两个无义突变、一个剪接突变和两个单拷贝数损失）和2个之前报道过的变异。截断变异体的听力结构在所有的频率均倾向于恶化，而非截断变异体则表现出高频听力损失，表明了DFNA10中存在基因型和表型的相关性。另外，EYA4变异引起的听力损失恶化为0.63dB每年，且与之前的报道相似。

原始出处：

Shinagawa J， Moteki H， Nishio SY et al. Prevalence and clinical features of hearing loss caused by EYA4 variants. Sci Rep. 27 Feb 2020.

 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044940, encodeId=bab2204494012, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed May 06 05:04:10 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250673, encodeId=edb112506e336, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306491, encodeId=aff1130649100, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342666, encodeId=70d8134266601, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-05-06 clmlylxy

    #临床特性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2044940, encodeId=bab2204494012, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed May 06 05:04:10 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250673, encodeId=edb112506e336, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306491, encodeId=aff1130649100, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342666, encodeId=70d8134266601, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-03-19 xinmeili

    #患病率#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2044940, encodeId=bab2204494012, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed May 06 05:04:10 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250673, encodeId=edb112506e336, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306491, encodeId=aff1130649100, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342666, encodeId=70d8134266601, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-03-19 ysjykql

    #听力#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2044940, encodeId=bab2204494012, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Wed May 06 05:04:10 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250673, encodeId=edb112506e336, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306491, encodeId=aff1130649100, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342666, encodeId=70d8134266601, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Thu Mar 19 02:04:10 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-03-19 12498dabm77暂无昵称

    #变异#

    0